PANCREATIC CANCER

This study tests a new treatment using specially engineered immune cells (TROP2 CAR-NK) delivered directly into the abdomen. It is for people with ovarian cancer that no longer responds to platinum chemotherapy, as well as certain rare ovarian and pancreatic cancers. The goal is …

This study tests whether combining two immunotherapy drugs (nivolumab and ipilimumab) with radiation therapy can control or shrink tumors in people with colorectal or pancreatic cancer that has specific genetic features (MSS or MSI-high). About 84 adults with advanced disease are…

This study tests a treatment plan for people with advanced pancreatic cancer that has spread to a major artery. Participants receive chemotherapy and radiation before surgery, then more chemo after. The goal is to see if this approach is safe and helps patients live longer. The t…

This study tests whether adding the drug surufatinib to standard chemotherapy can help shrink pancreatic tumors enough to allow successful surgery. It involves 29 adults with locally advanced or borderline resectable pancreatic cancer. The main goal is to see how many tumors can …

This early-phase study tests a new oral drug called E7386 in about 60 adults with advanced solid tumors (like desmoid tumors) that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. Researchers will also watch for any tu…

This study tests whether combining three immunotherapy drugs (domvanalimab, zimberelimab, and APX005M) can safely control metastatic pancreatic cancer. The trial enrolls 46 people whose cancer has spread and standard treatments have stopped working. Researchers will monitor side …

This study tests whether adding zolbetuximab to standard chemotherapy helps people with metastatic pancreatic cancer live longer. Zolbetuximab targets a protein (CLDN18.2) found in most pancreatic tumors, helping the immune system attack the cancer. About 393 adults whose cancer …

This study tests different combinations of immunotherapy drugs given before and after surgery for people with pancreatic cancer that can be removed. The goal is to see if these treatments can help the immune system fight the cancer better and improve outcomes. About 76 participan…

This phase 3 trial tests a new drug called daraxonrasib (RMC-6236) against standard treatments for people with metastatic pancreatic cancer that has already been treated. About 500 adults with a specific RAS gene mutation will be randomly assigned to receive either the new drug o…

This phase 2 study tests a personalized immune cell therapy called tumor-infiltrating lymphocytes (TIL) in 20 people with advanced solid cancers (like stomach, colon, or pancreatic cancer) that have not responded to standard treatments. Patients first receive chemotherapy to prep…

This study tests an experimental drug called LY3537982 in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drug is safe and shrinks tumors. About 540 participants with lung, colorectal, endometrial, ovarian, pancreatic, or bile …

This study tests if washing the abdomen with distilled water or saline right after removing a pancreatic tumor can help patients live longer. About 845 adults having surgery for pancreatic or related cancers are randomly assigned to one of three groups: washing with saltwater, wa…

This study tests an experimental drug called M9140 in people with advanced solid tumors (gastric, lung, or pancreatic cancer) that have a specific protein (CEACAM5). The drug is designed to deliver a toxin directly to cancer cells. About 250 adults will receive the drug alone or …

This phase 2 study tests the drug entrectinib in over 500 people with advanced solid tumors that have specific gene changes (NTRK, ROS1, or ALK fusions). The goal is to see if the drug can shrink tumors and control the disease. Participants have various cancer types, including lu…

This early-phase trial tests a new type of radiation called pulsed low-dose-rate (PLDR) for people with pancreatic cancer that cannot be removed right away. The radiation is given in small, spaced-out bursts along with the chemotherapy drug gemcitabine. The goal is to see if this…

This early-stage trial tests a new drug called LY4101174 in people with advanced solid tumors, including bladder, breast, and lung cancers. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The study will check if the drug is safe, tolerable, and ef…

This Phase 2 trial tests a chemotherapy regimen called NALIRIFOX combined with precise radiation (SBRT) in 42 people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this approach can delay cancer growth and improve survival. Partic…

This early-phase study tests a new treatment called EGFR-BATs for people with advanced pancreatic cancer that has not responded to standard chemotherapy. The treatment uses the patient's own immune cells, which are trained in a lab to better attack cancer cells. The main goal is …

This study tests whether giving chemotherapy both before and after surgery helps people with pancreatic cancer live longer compared to chemotherapy only after surgery. About 378 patients with resectable pancreatic cancer will be randomly assigned to one of two treatment schedules…

This study was designed to see if giving two chemotherapy drugs (gemcitabine and capecitabine) after surgery could help people with pancreatic cancer stay cancer-free longer. It was for patients who had already received chemotherapy before surgery. However, the trial was withdraw…

This phase 2 trial tests a new drug called ZN-c3 combined with the chemotherapy gemcitabine in 12 people with advanced pancreatic cancer that has worsened after platinum-based treatment. The goal is to see if the combination is safe and can slow cancer growth. Participants take Z…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy (mFOLFIRINOX) before surgery is safe and tolerable for people with pancreatic cancer that can be removed. About 20 adults with resectable or borderline resectable pancreatic cancer will rec…

This phase 2 trial tests whether giving a higher-than-standard dose of radiation, along with chemotherapy, can shrink pancreatic tumors enough to make them removable by surgery. The study includes 47 people with locally advanced pancreatic cancer that currently cannot be surgical…

This early-phase study tests a new type of radiation therapy (SCART) for people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to find the highest safe dose that can destroy the tumor while protecting nearby organs. About 24 participants wi…

This study tests a combination of two experimental drugs (AGEN1423 and botensilimab) with or without standard chemotherapy in people with advanced pancreatic cancer that has worsened after at least one prior treatment. The goal is to see if the combination can shrink tumors or sl…

This study tests a drug called trastuzumab deruxtecan (T-DXd) in people with various advanced cancers that have a protein called HER2. The goal is to see if the drug can shrink tumors and control the disease. About 477 participants with cancers like bladder, cervical, ovarian, an…

This study tests a new drug called futibatinib combined with standard immunotherapy and chemotherapy in people with advanced esophageal or pancreatic cancer. The goal is to see if the combination can shrink tumors and control the disease. About 53 adults who have not had prior tr…

This phase 2 trial tests a combination of two drugs, atezolizumab and cabozantinib, in 30 people with metastatic pancreatic cancer that has not responded to standard treatments. The goal is to see if the combination can shrink tumors or stop them from growing. Researchers will al…

This study tests a new drug called 9-ING-41, given alone or with chemotherapy, in adults with cancers that have not responded to standard treatments. The goal is to see if the drug is safe and can help control the disease. About 350 people with various advanced cancers, including…

This early-phase trial tests whether adding two immune-boosting drugs (canakinumab and tislelizumab) to standard chemotherapy can safely shrink pancreatic tumors before surgery. Nine adults with resectable or borderline resectable pancreatic cancer will receive the combination. T…

This early-stage trial tests a personalized cell therapy for people with advanced colorectal, pancreatic, or lung cancers that have a specific KRAS G12V mutation. The treatment involves taking a patient's own immune T cells, engineering them to recognize and attack cancer cells, …

This early study tests whether adding three cholesterol-lowering drugs (atorvastatin, ezetimibe, and evolocumab) to standard chemotherapy can slow or stop pancreatic cancer growth. Cancer cells need lots of cholesterol to grow, and this approach aims to starve them. The trial inc…

This study tests whether avatrombopag, a pill that boosts platelet production, can help people with gastrointestinal cancer who develop low platelets from chemotherapy. About 60 participants will receive either avatrombopag or a placebo. The goal is to see if the drug can raise p…

This Phase I trial tests a combination of two oral drugs, defactinib and VS-6766, in people with advanced solid tumors such as non-small cell lung cancer, low-grade serous ovarian cancer, and pancreatic cancer. The study aims to find the safest dose and evaluate how well the drug…

This study tests whether taking pancreatic enzymes (Pertzye) with meals can help people with metastatic pancreatic cancer maintain their body weight during chemotherapy. The trial includes 17 participants who are starting a standard chemo regimen called FOLFIRINOX. Researchers wi…

This study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…

This early-phase study tests a combination of two targeted drugs, palbociclib and gedatolisib, in people with advanced lung, pancreatic, head & neck, or other solid tumors that have stopped responding to standard treatments. The main goal is to find the safest dose and look for e…

This early-phase trial is testing a new type of cell therapy called P-MUC1C-ALLO1 for people with advanced solid tumors (like breast, ovarian, lung, or pancreatic cancer) that have not responded to other treatments. The therapy uses donor immune cells engineered to recognize and …

This phase III trial tests whether giving chemotherapy before and after surgery (perioperative) works better than giving it only after surgery (adjuvant) for people with pancreatic cancer that can be removed. The study involves 358 participants and uses a combination of four chem…

This study tests a 3-week course of radiation (using photons or protons) combined with chemotherapy for people with pancreatic cancer that hasn't spread. The goal is to see if this shorter treatment is safe and effective, either before surgery or as the main therapy. Researchers …

This early-stage study tests a new treatment called ACIT-1, which uses donated immune cells to help fight cancer. About 34 adults with pancreatic or other cancers will receive one of four doses to find the safest and most effective dose. The goal is to see if the therapy can safe…

This study tests a new drug called DZ-002 in adults with metastatic pancreatic cancer that has been stabilized with initial chemotherapy. The goal is to find the best dose and see if it is safe and can help keep the cancer from growing. Participants receive weekly IV infusions of…

This study tests a new drug, NUV-1511, in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the drug can shrink tumors in cancers like breast, prostate, pancreatic, and ovarian cancer. About 466 adults will ta…

This phase 2 trial is testing the safety and effectiveness of glipizide, a standard diabetes drug, for lowering blood sugar in people with pancreatic cancer. The study includes 29 participants with active pancreatic cancer and high blood sugar. Researchers will measure blood suga…

This early-phase trial is testing whether a personalized cancer vaccine, combined with an immunotherapy drug (atezolizumab) and chemotherapy, is safe for people with pancreatic cancer that has been surgically removed. The vaccine is made specifically for each patient based on the…

This phase IIb trial tests whether adding ATRA (a vitamin A derivative) to standard chemotherapy (gemcitabine and nab-paclitaxel) can help people with locally advanced pancreatic cancer live longer without their cancer growing. About 170 participants will receive either the combo…

This study tests a two-step treatment for people with pancreatic cancer that hasn't spread but can't be removed by surgery. First, patients receive a stronger chemotherapy cocktail (modified FOLFIRINOX), followed by precise, high-dose radiation (SBRT). The goal is to see if this …

This phase 2 trial tests whether adding a mix of immune-boosting drugs and special immune cells to standard chemotherapy can help people with advanced pancreatic cancer live longer. About 328 participants will receive either chemo alone or chemo plus the immunotherapy combo. The …

This study offers continued access to the cancer drug ruxolitinib (sometimes combined with other therapies) for people with pancreatic, colorectal, breast, or lung cancer who were already benefiting and stable in a prior Incyte-sponsored trial. Only 10 participants are enrolled, …

This trial tests an experimental drug called TST001, an antibody that targets a protein (Claudin 18.2) found on some cancer cells. It is being studied alone or combined with other treatments like nivolumab or chemotherapy in 150 people with advanced stomach, gastroesophageal junc…

This early-phase trial is testing a new treatment called LB1908, which uses a patient's own immune cells (T-cells) that have been modified in the lab to recognize and attack cancer cells that have a protein called claudin 18.2 on their surface. The study includes up to 56 adults …

This study tests a new device that delivers a special type of radiation directly into pancreatic tumors. It is for people with advanced pancreatic cancer that cannot be removed by surgery. The main goals are to see if the procedure is safe and possible to do. About 37 participant…

This early-phase trial is testing a vaccine that targets mutated KRAS proteins, combined with two immunotherapy drugs (nivolumab and ipilimumab), in 27 patients with pancreatic or colorectal cancer that has been surgically removed. The goal is to see if the vaccine can safely boo…

This study tests whether adding an experimental drug called PEGPH20 to standard chemotherapy can help shrink advanced pancreatic cancer. PEGPH20 breaks down hyaluronan, a substance that builds up in pancreatic tumors and may help them grow. The trial includes 110 people with adva…

This study tests a new drug called BT8009, alone or with another drug (pembrolizumab), in people with advanced solid tumors like bladder, breast, lung, or ovarian cancer. The drug targets a protein called Nectin-4 found on some cancer cells. The trial aims to find safe doses and …

This phase 2 trial tests whether adding the experimental drug Ampligen to standard care can help people with locally advanced pancreatic cancer that hasn't spread. About 90 participants who have completed at least four months of initial chemotherapy will receive either Ampligen p…

This study tests a new drug called ABTL0812 added to standard chemotherapy (gemcitabine and nab-paclitaxel) for people with advanced pancreatic cancer that has spread. The goal is to see if the combination is safe and works better than chemo alone. The trial was suspended, so res…

This study tests whether adding losartan (a blood pressure drug) and nivolumab (an immunotherapy) to standard chemotherapy and radiation can improve surgery outcomes for people with localized pancreatic cancer. About 168 participants with borderline resectable or locally advanced…

This trial tested stem cells taken from a patient's blood relative to treat pancreatic cancer, a fast-growing and often deadly disease. Only one patient was treated under a special expanded access program, which is now closed. The goal was to see if these donated stem cells could…

This early-stage trial tests a new oral drug called HBI-2376 in about 42 adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have KRAS or EGFR mutations and have stopped responding to standard treatments. The main goals are to find a safe dose and unde…

This early-phase trial tests a combination of two immunotherapy drugs (nivolumab and ipilimumab), a vaccine targeting TGFβ-15, and targeted radiation for pancreatic cancer that has not responded to standard treatments. The goal is to see if this mix can safely boost the immune sy…

This study aimed to test whether a person's own immune cells, modified in a lab to target specific cancer-related mutations (KRAS or TP53), could prevent advanced gastrointestinal cancers from coming back after standard treatment. Participants would have been randomly assigned to…

This study tests an experimental drug called ASKB589 in about 199 people with advanced solid tumors that have spread. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. People with stomach or pancreatic cancer are especially wanted for …

This phase 2 trial is testing a combination of three drugs—surufatinib, sintilimab, and a standard chemotherapy (nab-paclitaxel plus gemcitabine)—as a first treatment for people with advanced or metastatic pancreatic cancer. The study enrolled 32 participants and aims to see how …

This study compares two endoscopic procedures—EUS-BD and ERCP-BD—for draining blocked bile ducts caused by cancers near the pancreas or bile duct. Forty adults with distal malignant bile duct obstruction will be randomly assigned to one of the two procedures. The main goal is to …

This study tests an artificial intelligence model called PANDAPro that helps doctors spot pancreatic cancer on regular CT scans. Researchers will compare how well the AI finds cancers versus standard reading, and see if it catches tumors that were missed. The goal is to make scre…

This study aims to develop a blood test that predicts how well a patient's advanced pancreatic cancer will respond to different chemotherapy regimens. Researchers will analyze circulating tumor cells (CTCs) from 74 participants to see if the test can identify the most effective t…

This study aimed to compare two different needles used to take tissue samples from solid masses in the pancreas and digestive tract. The goal was to see which needle provides a more accurate diagnosis. The study was planned for adults needing this procedure, but it was withdrawn …

This study aimed to see if a simple blood test could spot early signs of pancreatic cancer in adults aged 50 and older who were recently diagnosed with type 2 diabetes. The plan was to enroll 10,000 participants and follow up with MRI scans for those with a positive test result. …

This study tests a special PET scan that uses a radioactive antibody (64Cu-M5A) to find cancers that produce a protein called CEA. The goal is to see if this scan can detect tumors that standard methods might miss. About 20 adults with CEA-positive cancers (such as breast, colon,…

This study aimed to test a new two-step PET imaging method to better detect cancers that produce a substance called CA19-9, such as pancreatic, bladder, and gastrointestinal tumors. The plan was to give patients an antibody followed by a radioactive tracer to highlight cancer cel…

This early-phase trial at Memorial Sloan Kettering is testing whether a special PET scan using an experimental tracer called 18F-FAC can show how much of the standard chemotherapy drug gemcitabine is taken up by pancreatic tumors. About 30 people with pancreatic ductal adenocarci…

This early-stage study tests an experimental vaccine designed to prevent cancer in adults with BRCA1 or BRCA2 gene mutations. The vaccine is given alone or with another drug, followed by a mild electric pulse to help it enter cells. Researchers want to see if it is safe and wheth…

This study looks at whether regular exercise and behavioral skills training can improve physical fitness and quality of life in people with pancreatic cancer who are getting chemotherapy or radiation before surgery. About 128 participants will take part at MD Anderson. The main g…

This study compares two procedures to relieve bile duct blockage caused by cancer. About 120 patients with pancreatic or bile duct cancer will be randomly assigned to get either a newer ultrasound-guided drainage or the standard ERCP procedure. The goal is to see which method has…

This study tests a program that lets cancer patients receive care at home while undergoing chemotherapy or radiation. It includes remote monitoring and home visits to reduce the need for hospital stays or emergency room visits. The goal is to see if this approach improves quality…

This study tests whether a supervised, video-based exercise program done at home during chemotherapy can help people with pancreatic cancer get stronger before surgery. About 58 patients will take part. The goal is to see if the program is safe and helps improve recovery.

This study tests a program called STRONG that gives pancreatic cancer patients extra support from a dietician and a Fitbit to track their food intake. The goal is to see if patients find the program helpful and easy to stick with while they are on chemotherapy. About 80 adults wi…

This study looks at whether adding a palliative care team early, before surgery, helps cancer patients manage symptoms like pain, fatigue, and anxiety. About 236 adults having certain abdominal cancer surgeries will either get usual care or usual care plus palliative support. The…

This study looks at whether ketorolac, a common anti-inflammatory drug, is safe and can help stabilize or increase weight in people with advanced pancreatic cancer who are experiencing cachexia (severe weight loss). About 28 participants will take the drug four times daily for fi…

This study tests whether using a FitBit and a mobile app can help people recover at home after surgery for stomach, liver, colon, or other GI cancers. About 107 patients will either use the devices plus standard care, or standard care alone. The app tracks activity and symptoms, …

This study tests whether starting palliative care early—right after diagnosis—improves quality of life for people with advanced pancreatic cancer. 250 participants receive regular visits from a palliative care team, plus referrals to exercise and nutrition experts. The goal is to…

This study is creating a biobank—a collection of blood, tumor tissue, and health data—from 500 people with pancreatic cancer. Researchers want to learn why some groups are affected more than others and how cachexia (severe weight loss) develops. Participants donate samples and fi…

This study looks at how frailty—a state of weakness and reduced physical function—affects the risk of severe side effects from chemotherapy in people aged 70 and older with cancer. Researchers will assess 160 patients using various tests for frailty, muscle loss, and overall heal…

This study collects tissue and blood samples from 1,200 adults with known or suspected cancer. The samples are taken during standard surgeries or biopsies, with no extra procedures. Researchers will compare cancerous and normal tissues to identify differences that could lead to n…

This study is a long-term follow-up for 400 people who previously received A2 Bio gene therapy for various solid tumors, including colorectal, lung, pancreatic, and ovarian cancers. No new treatment is given; instead, researchers will track participants over time to check for del…

This study reviews medical records from 300 cancer patients to see if the makeup of a tumor's surroundings (the tumor microenvironment) is linked to how well antibody-based therapies work. Researchers will analyze tissue samples and blood markers from patients with seven types of…

This study tests a new monitoring method for patients who have had pancreatic surgery. After surgery, a thin probe is placed near the surgical connection to measure chemicals that may signal a leak before symptoms appear. Half of the 201 participants will receive this monitoring …

This study looks at people with pancreatic cancer to find genetic factors that may increase risk. Researchers will collect medical and family history and test for gene mutations. The goal is to build a tool that can better identify who is at risk for this disease. 271 participant…

This study looks at a protein called DCAMKL-1, which may be a stem cell marker in pancreatic cancer. Researchers want to see how its levels change before and after treatment in 60 patients. The goal is to understand how current therapies affect this marker, not to test a new trea…

This pilot study is looking at whether dental erosion (loss of tooth enamel) could be a non-invasive biomarker for esophagogastric cancer and other cancers. Researchers will survey 174 participants (cancer patients and healthy volunteers) about diet, habits, and GERD symptoms, an…

This study looks at whether a website and a genetic family navigator can help more relatives of people with hereditary cancer get genetic testing. About 205 participants will use the online hub and work with a navigator to learn about their cancer risk. The goal is to see if this…

This study follows 99 adults with pancreatic cancer who are having surgery to remove their tumor. Researchers want to see if a narrowed celiac artery (celiac axis stenosis) leads to more complications after the operation. The goal is to better understand this risk so surgeons can…

This study collects leftover tissue, blood, and other fluid samples from 6,000 people with benign or malignant tumors of the soft tissue, gastrointestinal tract, or abdomen. Researchers will use these samples in lab studies to better understand the causes, prevention, diagnosis, …

This study brings together cancer experts to agree on standard definitions for key measurements used in cancer clinical trials, such as how long patients live without their cancer getting worse. Currently, different trials define these measurements in different ways, making it ha…

This study looks at whether analyzing CT scans with a computer technique called radiomics can predict which patients with advanced pancreatic cancer will not respond to chemotherapy. Researchers will study 400 patients and track survival over time. The goal is to find early signs…

This study is creating a large, detailed registry of people with pancreatic cancer. Researchers will collect information from medical records and follow new patients over time. The goal is to gather real-world data to better understand the disease and its treatment, which could l…

This study tests a new computer tool that uses CT scans to predict how blood flow will change during major abdominal surgery for pancreatic cancer. Currently, doctors must use an invasive procedure called angiography to check blood flow, which carries risks. The tool aims to make…